Call for papers for an open special issue on small/microRNAs:
Small RNAs: Revolutionizing the Genomics Landscape
The editors invite researchers to contribute original research articles as well as review articles focused on the use, development, or the application of genomics tools for investigating the role of small RNAs at the whole-genome level. The editors will be interested in review manuscripts that describe biology of noncoding RNAs as well as bioinformatics and computational biology based approaches for analyzing small RNAs datasets.
Potential topics include, but are not limited to:
- Small RNAs and microRNAs next-generation sequencing data analysis
- Identification and classification of miRNA genes and targets
- Small RNAs regulatory networksSoftware and tool development for small RNA data analysis
- Comparative evolution of small RNAs
- Small RNAs players in cancer and plant stress responses
Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/ijg/guidelines/.
Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ijg/rnas/ according to the following timetable:
- Manuscript Due: Friday, 2 August 2013
- First Round of Reviews: Friday, 25 October 2013
- Publication Date: Friday, 20 December 2013
For the full details please see:
http://www.hindawi.com/journals/ijg/si/431758/cfp/
Incoming search terms for this article:
NEW YORK, April 8, 2013 /PRNewswire/ – Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C. The abstract is titled “Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients.” It will be presented during Poster Session 47 from 1 to 5 p.m. EDT on April 8 by Johan Skog, Ph.D., the newly appointed chief scientific officer of Exosome Diagnostics.
In this study, Exosome Diagnostics used its proprietary RNA-extraction technology to measure a broad spectrum of full-length mRNA and microRNA from low volumes (2 mL) of frozen, archival serum from brain cancer patients enrolled in a therapeutic clinical trial. Prior to the introduction of Exosome Diagnostics’ technology, similar biomarker analysis would have required performing invasive brain tissue biopsies.
This clinical study represents the third biofluid in which Exosome Diagnostics has demonstrated [click to continue…]
Incoming search terms for this article:
Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S’ Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials
HOERSHOLM, Denmark and SAN DIEGO, March 27, 2013 /PRNewswire/ — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the publication of study results online in the New England Journal of Medicine (NEJM). The publication highlights the potential benefits of miravirsen, a host-targeted, pan-HCV genotype anti-viral agent and the first microRNA-targeted drug to enter clinical trials for the treatment of Hepatitis C virus (HCV). In the study, miravirsen, given as a four-week monotherapy treatment, provided robust dose-dependent antiviral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL). The effect was sustained well beyond the end of therapy.
Clinical data from the Phase 2a study demonstrated the following:
- Miravirsen was safe, well tolerated and provided prolonged antiviral activity well after the last dose of miravirsen monotherapy (x5 weekly injections)
- There were no signs of viral resistance
- Adverse events were infrequent, mild and did not lead to study drug discontinuation
- There were no dose limiting toxicities or discontinuations due to adverse events
- Miravirsen was associated with dose-dependent reductions in [click to continue…]
Incoming search terms for this article:
Award Strengthens Growing Portfolio of microRNAs in Viral Infection
PHILADELPHIA and REHOVOT, Israel, March 18, 2013 /PRNewswire/ – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent Office related to U.S. Patent Application No. 12/517,760 entitled “Nucleic Acids Involved in Viral Infection.”
The allowed claims include a method of reducing the amount of virus replication in a target cell infected with the virus by introducing into the target cell an effective amount of miR-210, its variants or its precursor.
“We are delighted to add this new patent to our expanding intellectual property portfolio of microRNAs in viral infection. This newly granted patent further solidifies our dominant patent position in microRNAs and opens up other disease states where microRNAs may be of great benefit. Many of the current viral therapeutics suffer from low efficacy, toxicity and induction [click to continue…]
Incoming search terms for this article:
Researchers at the University of Texas Southwestern Medical Center and Baylor Institute for Immunology Research have identified a novel expression signature in patients with DiGeorge Syndrome. DiGeorge Syndrome occurs because of a chromosomal deletion in 22q11.2, resulting in the hemizygous deletion of > 60 genes and 4 microRNAs. Peripheral blood taken from 31 DiGeorge Syndrome patients and 22 normal controls was analyzed for microRNA expression signatures. Van Oers’ group identified a panel of microRNA that is deregulated in the peripheral blood of DiGeorge patients as compared to controls, and in particular, miR-185 was observed to have reduced expression (<60%) in DiGeorge patients. miR-185 is a microRNA gene located within the 22q11.2 gene locus.
The authors note that evaluating miR-185 expression levels in blood may be a faster and more reliable method to diagnose patients with DiGeorge Syndrome and can be used as a marker for 22q11.2 deletions. Several patients presenting with DiGeorge-like symptoms had normal expression levels of miR-185, and follow-up FISH analysis confirmed these patients had no deletion of 22q11.2. Considering DiGeorge patients can present with several different clinical symptoms, the use of association studies and mosaic cluster analyses has provided evidence for the first time that miR-185 expression can distinguish patients with true DiGeorge 22q11.2 deletions and patients with other genetic abnormalities presenting with similar symptoms. The study concludes by noting that microRNA profiling can be useful in helping researchers and clinicians identify important biomarkers for other abnormal chromosomal diseases presenting with heterogeneous symptoms like DiGeorge Syndrome.
M. Teresa de la Morena, Jennifer L. Eitson, Igor M. Dozmorov, Serkan Belkaya, Ashley R. Hoover, Esperanza Anguiano, M. Virginia Pascual, Nicolai S.C. van Oers, Signature MicroRNA Expression Patterns Identified in Humans with 22q11.2 Deletion/DiGeorge Syndrome, Clinical Immunology (2013), doi:10.1016/j.clim.2013.01.011
Article Link: http://www.sciencedirect.com/science/article/pii/S1521661613000223
Incoming search terms for this article:
Loading ...
